- Featured Product
- KD/KO Validated
PD-L1/CD274 Monoclonal antibody
PD-L1/CD274 Monoclonal Antibody for FC, IF, IHC, WB,ELISA
Host / Isotype
Mouse / IgG1
Reactivity
human, mouse, pig, rat
Applications
WB, IHC, IF, FC,ELISA
Conjugate
Unconjugated
CloneNo.
2B11D11
Cat no : 66248-1-Ig
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | A375 cells, human placenta tissue, pig lung tissue, human skeletal muscle tissue, HepG2 cells, THP-1 cells, RAW 264.7 cells, A549 cells, K-562 cells, HSC-T6 cells |
| Positive IHC detected in | human tonsillitis tissue, mouse heart tissue, human lung cancer tissue, human placenta tissue, human heart tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF detected in | HeLa cells |
| Positive FC detected in | MDA-MB-231 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:10000 |
| Immunohistochemistry (IHC) | IHC : 1:5000-1:20000 |
| Immunofluorescence (IF) | IF : 1:50-1:500 |
| Sample-dependent, check data in validation data gallery | |
Published Applications
| KD/KO | See 2 publications below |
| WB | See 37 publications below |
| IHC | See 30 publications below |
| IF | See 14 publications below |
| FC | See 2 publications below |
Product Information
66248-1-Ig targets PD-L1/CD274 in WB, IHC, IF, FC,ELISA applications and shows reactivity with human, mouse, pig, rat samples.
| Tested Reactivity | human, mouse, pig, rat |
| Cited Reactivity | human, mouse |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | PD-L1/CD274 fusion protein Ag12443 |
| Full Name | CD274 molecule |
| Calculated molecular weight | 290 aa, 33 kDa |
| Observed molecular weight | 45-50 kDa |
| GenBank accession number | BC074984 |
| Gene symbol | CD274 |
| Gene ID (NCBI) | 29126 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein G purification |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis.
What is the molecular weight of PD-L1?
Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176-290 aa).
What are the isoforms of PD-L1?
According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions.
What is the subcellular localization and tissue specificity of PD-L1?
It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues.
What is the function of PD-L1 in immune responses?
PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681).
How can PD-L1's implication in cancer be used as a drug target?
In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375).
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for PD-L1/CD274 antibody 66248-1-Ig | Download protocol |
| IHC protocol for PD-L1/CD274 antibody 66248-1-Ig | Download protocol |
| IF protocol for PD-L1/CD274 antibody 66248-1-Ig | Download protocol |
| FC protocol for PD-L1/CD274 antibody 66248-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Antiviral Res Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection. | ||
J Immunol FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway. | ||
Otolaryngol Head Neck Surg PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma. | ||
JAAD Case Rep A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery. | ||
Biochim Biophys Acta Mol Basis Dis MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity. |
